About Rhythm Pharmaceuticals

Learn about Rhythm’s dedication to pioneering research and development of treatments for rare MC4R pathway diseases and our clinical development pipeline.
Rhythm’s Clinical Development Program
Acquired hypothalamic obesity

Learn more about acquired hypothalamic obesity, a disease characterized by accelerated and sustained weight gain that occurs most frequently after hypothalamic injury, and its unique pathophysiology involving impaired MC4R pathway signaling leading to dysregulated energy balance.
Frequency of Obesity-Associated Gene Variants From Uncovering Rare Obesity®

Learn about the frequency of obesity-associated gene variants uncovered in Rhythm’s Uncovering Rare Obesity® testing program
Uncovering Rare Obesity®
Learn about Uncovering Rare Obesity® program, a genetic testing program that helps identify rare genetic diseases of obesity. https://uncoveringrareobesity.com
MC4R pathway-associated obesities

Learn about the melanocortin-4 receptor (MC4R) pathway that regulates energy balance, the clinical characteristics of several rare genetic diseases, and when to consider genetic testing.
Bardet-Biedl syndrome (BBS)

Learn about the clinical features, prevalence, pathophysiology, and diagnosis of Bardet-Biedl syndrome, a rare genetic disease.
Hyperphagia overview

Learn how to identify hyperphagia in your patients with rare MC4R pathway diseases, and to determine if/how it is impacting their daily lives.